ClinicalTrials.gg
RecruitingNCT06085612Updated Oct 23, 2023

Impact of Significant Carotid Stenosis on Retinal Perfusion Measured Via Automated Retinal Oximetry

An observational study in Stroke, Ischemic and Stenosis, Carotid, sponsored by University Hospital Olomouc. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by University Hospital Olomouc · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Ischemic Stroke with a site in Czechia — 8 open to participants now, 10 under way, 1 of them phase 3. Ischemic Stroke · Czechia.

Started
2023
with 5 others
Observational
7 of 29
4 open now
Registered
28th of 29
by date
Lead sponsor
2 of 29
University Hospital Olomouc

Among the 29 studies in Ischemic Stroke with a site in Czechia, this one is one of 6 that started in 2023, is one of 7 observational ones, and was the 28th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

8 of the 29 studies in Ischemic Stroke with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Ischemic Stroke with a site in Czechia, or all of them as a file.
02

Study summary

Background: Large vessel carotid stenosis represent significant cause of ischaemic stroke. Indication for surgical revascularisation treatment relies on severity stenosis and clinical symptoms. Mild clinical symptoms such as transient ischemic attack, amaurosis fugax or minor stroke preceded large strokes in only 15% of cases.

Aim: The aim of this prospective study is to evaluate whether retinal perfusion is impacted in significant carotid stenosis. Automated retinal oximetry could be used to better evaluate perfusion in post-stenotic basin. The investigators presume the more stenotic blood vessel, the more reduced retinal perfusion is resulting in adaptive changes such as higher arteriovenous saturation difference due to greater oxygen extraction. This could help broaden the indication spectrum for revascularisation treatment for carotid stenosis.

Methods: The investigators plan to enroll 50 patients a year with significant carotid stenosis and cross-examine them with retinal oximetry. Study group will provide both stenotic vessels and non-stenotic vessels forming the control group. Patients with significant carotid stenosis will undergo an MRI examination to determine the presence of asymptomatic recent ischaemic lesions in the stenotic basin, and the correlation to oximetry parameters.

Statistics: Correlation between the severity of stenosis and retinal oximetry parameters will be compared to the control group of non-stenotic sides with threshold of 70%, respectively 80% and 90% stenosis. Data will be statistically evaluated at the 5% level of statistical significance. Results will be then reevaluated with emphasis on MRI findings in the carotid basin.

Conclusion: This prospective case control study protocol wil be used to launch a trial assessing the relationship between significant carotid stenosis and retinal perfusion measured via automated retinal oximetry.

03

Conditions studied

  • Stroke, Ischemic
  • Stenosis, Carotid

Keywords

  • automated retinal oximetry
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Study population will include patients examined in Neurosonological laboratory in Neurology department of University Hospital Olomouc,

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study population will include patients examined in ultrasound laboratory in Neurology department of University Hospital Olomouc, regardless of incidental finding of stenosis, examination due to acute symptoms or regular checkup of known stenosis.

Exclusion criteria

Exclusion Criteria:

  • patients unable undergo ophthalmological examination properly, especially on automated retinal oximetry.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Internal Carotid Artery Stenosis

    Group of patients with internal carotid stenosis detected via ultrasound examination.

    Diagnostic Test: Automated retinal oximetry

  • Non stenotic Internal Carotid Artery

    Group of patients without internal carotid stenosis on ultrasound examination.

    Diagnostic Test: Automated retinal oximetry

Interventions

  • Diagnostic testAutomated retinal oximetry

    Non invasive standard examination on automated retinal oximetry.

06

What researchers measure

Primary outcomes

  1. Arterio-venous oxygen difference in retinal blood vessels measured by automated retinal oximetry.

    To establish whether arterio-venous difference in the stenotic basin increases with the severity of stenosis and/or these changes vary depending on the severity of stenosis.

    Time frame: 2028

Secondary outcomes

  1. Correlation with MRI ischaemic lesions

    with clinically symptomatic and asymptomatic carotid stenosis correlated to MRI findings of ipsilateral ischaemic lesions in the stenotic basin.

    Time frame: 2029

07

Study locations

1 of 1 sites recruiting
  • University Hospital Olomouc
    Olomouc, 775 20, Czechia
    Recruiting
    • Michal Kral, MD · Contactmichal.kral@fnol.cz · +420 604 171 594
    • Michal Kral, MD · Principal investigator
    • Daniel Sanak, MD,PhD · Sub investigator
    • Petr Polidar, MD · Sub investigator
    • Barbora Pašková, MD · Sub investigator
    • Marta Karhanová, MD, Ph.D. · Sub investigator
    • Tomáš Dorňák, MD, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 48 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 17, 2023
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06085612
Lead sponsor
University Hospital Olomouc
Responsible party
Michal Kral (Principal Investigator, University Hospital Olomouc) — Principal investigator
First posted
Oct 17, 2023
Start date
Jan 1, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 23, 2023

Study contacts

Michal Král, MD., Ph.D.
Contact
michal.kral@fnol.cz
+420604171594

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion